US Federal 2025-2026 Regular Session

US Federal Senate Bill SB1891

Introduced
5/22/25  

Caption

PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

Impact

The implementation of SB1891 is expected to have a significant impact on the pharmaceutical sector by creating a more favorable economic environment for the production of generic drugs and biosimilars. By offering credits equal to a percentage of the value added to eligible components produced in the U.S., the bill is designed to incentivize domestic manufacturing. This could, in turn, help lower drug costs for consumers and enhance market competition, potentially increasing access to lifesaving medications.

Summary

SB1891, known as the Producing Incentives for Long-term production of Lifesaving Supply of medicine Act (PILLS Act), aims to amend the Internal Revenue Code of 1986 by establishing tax credits to encourage the domestic production of generic drugs and biosimilars. This bill seeks to provide economic incentives for pharmaceutical companies to manufacture these essential medications in the United States, aiming to reduce reliance on foreign production and to enhance the availability of affordable drugs for patients.

Contention

However, the bill might not be without contention. Critics may express concerns about the potential for manufacturers to take advantage of tax credits without ensuring the quality or availability of drugs. There could also be fears that the focus on incentivizing domestic production may lead to increased regulatory scrutiny or burdens on companies, particularly smaller manufacturers that might struggle with compliance costs. Additionally, the bill's safeguards against benefiting foreign entities of concern, as defined in relevant defense legislation, may raise discussions about the balance of national security interests with pharmaceutical availability.

Companion Bills

US HB1396

Same As PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

Previously Filed As

US HB1396

PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

US SB4189

INSULIN Act of 2026 Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026

US SB1553

Authorizes incentives for producing certain critical materials and pharmaceuticals

US HB8143

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.

US SB4323

Ensuring Access to Lower-Cost Medicines for Seniors Act

US SB140

To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.

US SB34

Prescription drugs; creating the Access to Lifesaving Medicines Act; prohibiting certain costs and requiring rebates under certain plans. Effective date.

US SB34

Prescription drugs; creating the Access to Lifesaving Medicines Act; prohibiting certain costs and requiring rebates under certain plans. Effective date.

US HB6143

PRECISE Act Producing Responsible Energy and Conservation Incentives and Solutions for the Environment Act

US SB1616

PRECISE Act of 2025 Producing Responsible Energy and Conservation Incentives and Solutions for the Environment Act of 2025

Similar Bills

No similar bills found.